Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Advanced NSCLC Clinical Trial

— NSCLC  

Official title:

Nivolumab (Anti-PD1 Antibody) and Ipilimumab (Anti-CTLA4 Antibody) in Combination With Immunogenic Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04043195
• Other study ID #: 181485
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: August 14, 2019
• Est. completion date: December 2025

Study information

• Verified date: August 2023
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).

Nivolumab (Opdivo®) is approved by the Food and Drug Administration (FDA) for the treatment of metastatic (the cancer has spread) NSCLC. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies bind to other proteins, such as PD-1 (programmed cell death-1), on immune cells, which allows the immune cells to continue working against the tumor.

Ipilumumab (Yervoy®) is also a monoclonal antibody, but binds to a protein called CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).

Oxaliplatin is a type of immunogenic chemotherapy, which may increase the body's immune response to the cancer. Both are approved for treatment of other types of cancers, but not in patients with NSCLC.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: December 2025
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

The following list is a summary. Additional criteria apply.

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for study entry.

• At least 18 years or older

• Histologically or cytologically confirmed, advanced non-squamous or squamous NSCLC

• Last line of therapy for advanced non-squamous or squamous NSCLC must be with an anti-PD1 or PDL1 antibody with confirmed progression on or after that treatment. Patients may have received no more than 3 lines of prior therapy including no more than 2 prior lines of therapy containing a PD-(L)-2 antibody. Patients must have received prior cisplatin or carboplatin based doublet chemotherapy.

• Measurable disease, as defined by RECIST v1.1

• Adequate hematologic and end-organ function, defined by the laboratory test results within 14 days prior to randomization:

• For female patients of childbearing potential and male patients with partners of childbearing potential, agreement to use a highly effective form(s) of contraception during study treatment that results in a low failure rate of <1% per year when used consistently and correctly. Female patients should continue contraception use for 5 months after the last dose of nivolumab and ipilimumab and for 6 months after the last dose of oxaliplatin. Make patients treated with chemotherapy should continue contraception use for 7 months after the last dose of chemotherapy. Men should refrain from donating sperm during this same period. Such methods include combined (estrogen and progestogen containing) hormonal contraception, with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the study duration), and sexual abstinence.

• Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this study if they have a partner of childbearing potential. Male patients must always use a condom.

• Women who are not postmenopausal (>12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.

Exclusion Criteria:

General Medical Exclusions

• Women who are pregnant, lactating, or intending to become pregnant during the study.

• History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

• History of autoimmune disease

• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.

• Major surgical procedure other than for diagnosis within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study.

• Prior allogeneic bone marrow transplantation or solid organ transplantation.

Exclusion Criteria Related to Medications

• Treatment with any approved anti-cancer therapy within 2 weeks prior to initiation of study treatment.

• Treatment with any other investigational agent with therapeutic intent within 21 days prior to enrollment.

• Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to enrollment.

Related Conditions & MeSH terms

• Advanced NSCLC

Intervention

Drug:
• Nivolumab
240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
• Oxaliplatin
65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
• Ipilimumab
1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles

Locations

Country	Name	City	State
United States	UC San Diego Moores Cancer Center	La Jolla	California

Sponsors (1)

Lead Sponsor	Collaborator
Hatim Husain

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (ORR)	To estimate ORR by RECIST 1.1	4 months
Secondary	Overall survival (OS)		1 and 2 year
Secondary	Progression-free survival (PFS)		1 year